Geographic Atrophy Clinical Trial Pipeline Appears Robust With 23+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight's, "Geographic Atrophy Pipeline Insight, 2025" report provides comprehensive insights about 23+ companies and 25+ pipeline drugs in Geographic Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Geographic Atrophy Pipeline? Click here to explore the therapies and trials making headlines @ Geographic Atrophy Pipeline Outlook Report- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Geographic Atrophy Pipeline Report
• On 10 November 2025, Astellas Pharma Inc. announced a study is for people in Japan of 40 years of age or older, who have geographic atrophy. The main aim of this study is to collect information about the safety of ASP3021 and how well people tolerate treatment with ASP3021. During the study, people will receive monthly injections of ASP3021 for 12 months. ASP3021 is given by injection into the affected eye. This procedure is called an intravitreal injection.
• On 07 November 2025, Janssen Research & Development LLC conducted a study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
• DelveInsight's Geographic Atrophy Pipeline report depicts a robust space with 23+ active players working to develop 25+ pipeline therapies for Geographic Atrophy treatment.
• The leading Geographic Atrophy Companies such as Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis and others.
• Promising Geographic Atrophy Therapies such as OCU410, SAR446597, BI 1584862, Tinlarebant, OpRegen, Vonaprument, NGM621, Prednisone, ANX007 and others.

Want to know which companies are leading innovation in Geographic Atrophy? Dive into the full pipeline insights @ Geographic Atrophy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Geographic Atrophy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Geographic Atrophy Pipeline Report also highlights the unmet needs with respect to the Geographic Atrophy.

Geographic Atrophy Overview
Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The disease is characterized by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium and choriocapillaris. It starts typically in the perifoveal region and expands to involve the fovea with time, leading to central scotomas and permanent loss of visual acuity. It is bilateral in most cases.

Geographic Atrophy Emerging Drugs Profile
• IONIS-FB-LRx: Ionis Pharmaceuticals
IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including dry age-related macular degeneration (AMD). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in capillaries in the eye.

• Zimura: IVERIC bio
Zimura (avacincaptad pegol) is an investigational drug product designed to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells. This potential mechanism is the rationale for Zimura as a potential therapy for geographic atrophy secondary to age-related macular degeneration.

If you're tracking ongoing Geographic Atrophy Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Geographic Atrophy Treatment Drugs- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Geographic Atrophy Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Geographic Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Geographic Atrophy Treatment.
• Geographic Atrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Geographic Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Geographic Atrophy market.

Geographic Atrophy Companies
Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis and others.

Geographic Atrophy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Geographic Atrophy Products have been categorized under various Molecule types such as,
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

From emerging drug candidates to competitive intelligence, the Geographic Atrophy Pipeline Report covers it all - check it out now @ Geographic Atrophy Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Geographic Atrophy Pipeline Report
• Coverage- Global
• Geographic Atrophy Companies- Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis and others.
• Geographic Atrophy Therapies- OCU410, SAR446597, BI 1584862, Tinlarebant, OpRegen, Vonaprument, NGM621, Prednisone, ANX007 and others.
• Geographic Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Geographic Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Geographic Atrophy Treatment landscape in this detailed analysis @ Geographic Atrophy Emerging Drugs and Major Players- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Geographic Atrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Geographic Atrophy - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Zimura: IVERIC bio
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. IONIS-FB-LRx: Ionis Pharmaceuticals
12. Drug profiles in the detailed report.....
13. Inactive Products
14. Geographic Atrophy Key Companies
15. Geographic Atrophy Key Products
16. Geographic Atrophy- Unmet Needs
17. Geographic Atrophy- Market Drivers and Barriers
18. Geographic Atrophy- Future Perspectives and Conclusion
19. Geographic Atrophy Analyst Views
20. Geographic Atrophy Key Companies
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.